Low-pass Whole Genome Imputation Enables the Characterization of Polygenic Breast Cancer Risk in the Indigenous Arab Population - Al-Jumaan, Mohammed; Chu, Hoyin; Al-Sulaiman, Abdullah; Camp, Sabrina Y.; Han, Seunghun; Gillani, Riaz; Al Marzooq, Yousef; Almulhim, Fatmah; Vatte, Chittibabu; Al Nemer, Areej; Almuhanna, Afnan; Van Allen, Eliezer M; et al. (medRxiv, 2022)
The indigenous Arab population has traditionally been underrepresented in cancer genomics studies, and as a result the polygenic risk landscape of breast cancer in the population remains elusive. Here we show by utilizing low-pass whole genome sequencing (lpWGS), we can accurately impute population-specific variants with high exome concordance (median dosage correlation: 0.9459, Interquartile range: 0.9410-0.9490) and construct breast cancer burden-sensitive polygenic risk scores (PRS) using publicly available resources. After adjusting the PRS to the Arab population, we found significant associations between PRS performance in risk prediction and first-degree relative breast cancer history prediction (Spearman rho=0.43, p = 0.03), where breast cancer patients in the top PRS decile are 5.53 (95% CI: 1.76-17.97, p = 0.003) times more likely to also have a first degree relative diagnosed with breast cancer compared to those in the middle deciles. In addition, we found evidence for the genetic liability threshold model of breast cancer where among patients with a family history of breast cancer, pathogenic rare variant carriers had significantly lower PRS than non-carriers (p = 0.0205, M.W.U.) while for non-carriers every standard deviation increase in PRS corresponded to 4.52 years (95% CI: 8.88-0.17, p = 0.042) earlier age of presentation. Overall, our study provides a viable strategy utilizing lpWGS to assess polygenic risk in an understudied population and took steps in addressing existing global health disparities.Competing Interest StatementE.M.V.A. holds consulting roles with Tango Therapeutics, Genome Medical, Genomic Life, Enara Bio, Manifold Bio, Monte Rosa, Novartis Institute for Biomedical Research, Riva Therapeutics and Serinus Bio; he receives research support from Novartis, Bristol-Myers Squibb and Sanofi; he has equity in Tango Therapeutics, Genome Medical, Genomic Life, Syapse, Enara Bio, Manifold Bio, Microsoft, Monte Rosa, Riva Therapeutics and Serinus Bio; he has filed institutional patents on chromatin mutations, immunotherapy response, and methods for clinical interpretation. R.G. has equity in Google, Microsoft, Amazon, Apple, Moderna, Pfizer, and Vertex Pharmaceuticals. The other authors declare no competing interests.Funding StatementThis work was supported by King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia, grants #12-MED2226-46 and #11-MED2101-46, the Department of Defense Physician Research Award (W81XWH-21-1-0084, PC200150) (S.H.A), and the Department of Defense Idea Development Award - Early-Career Investigator (KC210042/W81XWH-22-1-0455) (S.H.A). The funding organizations were not responsible for the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB#2019-01-109 of Imam Abdulrahman Bin Faisal University gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors